Format
Items per page
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 1 to 20 of 31

2.

Effect of daily aciclovir on HIV disease progression in individuals in Rakai, Uganda, co-infected with HIV-1 and herpes simplex virus type 2: a randomised, double-blind placebo-controlled trial.

Reynolds SJ, Makumbi F, Newell K, Kiwanuka N, Ssebbowa P, Mondo G, Boaz I, Wawer MJ, Gray RH, Serwadda D, Quinn TC.

Lancet Infect Dis. 2012 Jun;12(6):441-8. doi: 10.1016/S1473-3099(12)70037-3. Epub 2012 Mar 19.

3.

Valacyclovir suppressive therapy reduces plasma and breast milk HIV-1 RNA levels during pregnancy and postpartum: a randomized trial.

Drake AL, Roxby AC, Ongecha-Owuor F, Kiarie J, John-Stewart G, Wald A, Richardson BA, Hitti J, Overbaugh J, Emery S, Farquhar C.

J Infect Dis. 2012 Feb 1;205(3):366-75. doi: 10.1093/infdis/jir766. Epub 2011 Dec 6.

4.

High-dose valacyclovir HSV-2 suppression results in greater reduction in plasma HIV-1 levels compared with standard dose acyclovir among HIV-1/HSV-2 coinfected persons: a randomized, crossover trial.

Mugwanya K, Baeten JM, Mugo NR, Irungu E, Ngure K, Celum C.

J Infect Dis. 2011 Dec 15;204(12):1912-7. doi: 10.1093/infdis/jir649. Epub 2011 Oct 12.

5.

Prevention of mother-to-child transmission of HIV and the health-related Millennium Development Goals: time for a public health approach.

Schouten EJ, Jahn A, Midiani D, Makombe SD, Mnthambala A, Chirwa Z, Harries AD, van Oosterhout JJ, Meguid T, Ben-Smith A, Zachariah R, Lynen L, Zolfo M, Van Damme W, Gilks CF, Atun R, Shawa M, Chimbwandira F.

Lancet. 2011 Jul 16;378(9787):282-4. doi: 10.1016/S0140-6736(10)62303-3. No abstract available.

PMID:
21763940
6.

Optimal time on HAART for prevention of mother-to-child transmission of HIV.

Chibwesha CJ, Giganti MJ, Putta N, Chintu N, Mulindwa J, Dorton BJ, Chi BH, Stringer JS, Stringer EM.

J Acquir Immune Defic Syndr. 2011 Oct 1;58(2):224-8. doi: 10.1097/QAI.0b013e318229147e.

7.

Factors influencing retention in care after starting antiretroviral therapy in a rural South African programme.

Boyles TH, Wilkinson LS, Leisegang R, Maartens G.

PLoS One. 2011 May 3;6(5):e19201. doi: 10.1371/journal.pone.0019201.

8.

Implementation and outcomes of an active defaulter tracing system for HIV, prevention of mother to child transmission of HIV (PMTCT), and TB patients in Kibera, Nairobi, Kenya.

Thomson KA, Cheti EO, Reid T.

Trans R Soc Trop Med Hyg. 2011 Jun;105(6):320-6. doi: 10.1016/j.trstmh.2011.02.011. Epub 2011 Apr 20.

PMID:
21511317
9.

The cost-effectiveness of herpes simplex virus-2 suppressive therapy with daily aciclovir for delaying HIV disease progression among HIV-1-infected women in South Africa.

Vickerman P, Devine A, Foss AM, Delany-Moretlwe S, Mayaud P, Meyer-Rath G.

Sex Transm Dis. 2011 May;38(5):401-9. doi: 10.1097/OLQ.0b013e31820b8bc8.

PMID:
21317689
10.

Herpes simplex virus type 2 suppressive therapy with acyclovir or valacyclovir does not select for specific HIV-1 resistance in HIV-1/HSV-2 dually infected persons.

Baeten JM, Lingappa J, Beck I, Frenkel LM, Pepper G, Celum C, Wald A, Fife KH, Were E, Mugo N, Sanchez J, Essex M, Makhema J, Kiarie J, Farquhar C, Corey L.

J Infect Dis. 2011 Jan 1;203(1):117-21. doi: 10.1093/infdis/jiq013.

11.

Use of acyclovir for suppression of human immunodeficiency virus infection is not associated with genotypic evidence of herpes simplex virus type 2 resistance to acyclovir: analysis of specimens from three phase III trials.

Watson-Jones D, Wald A, Celum C, Lingappa J, Weiss HA, Changalucha J, Baisley K, Tanton C, Hayes RJ, Marshak JO, Gladden RG, Koelle DM.

J Clin Microbiol. 2010 Oct;48(10):3496-503. doi: 10.1128/JCM.01263-10. Epub 2010 Aug 11.

12.

Long-term impact of acyclovir suppressive therapy on genital and plasma HIV RNA in Tanzanian women: a randomized controlled trial.

Tanton C, Weiss HA, Rusizoka M, Legoff J, Changalucha J, Baisley K, Mugeye K, Everett D, Belec L, Clayton TC, Ross DA, Hayes RJ, Watson-Jones D.

J Infect Dis. 2010 May 1;201(9):1285-97. doi: 10.1086/651696.

13.

Pretreatment CD4 cell slope and progression to AIDS or death in HIV-infected patients initiating antiretroviral therapy--the CASCADE collaboration: a collaboration of 23 cohort studies.

Wolbers M, Babiker A, Sabin C, Young J, Dorrucci M, ChĂȘne G, Mussini C, Porter K, Bucher HC; CASCADE Collaboration Members.

PLoS Med. 2010 Feb 23;7(2):e1000239. doi: 10.1371/journal.pmed.1000239.

14.

Daily acyclovir for HIV-1 disease progression in people dually infected with HIV-1 and herpes simplex virus type 2: a randomised placebo-controlled trial.

Lingappa JR, Baeten JM, Wald A, Hughes JP, Thomas KK, Mujugira A, Mugo N, Bukusi EA, Cohen CR, Katabira E, Ronald A, Kiarie J, Farquhar C, Stewart GJ, Makhema J, Essex M, Were E, Fife KH, de Bruyn G, Gray GE, McIntyre JA, Manongi R, Kapiga S, Coetzee D, Allen S, Inambao M, Kayitenkore K, Karita E, Kanweka W, Delany S, Rees H, Vwalika B, Magaret AS, Wang RS, Kidoguchi L, Barnes L, Ridzon R, Corey L, Celum C; Partners in Prevention HSV/HIV Transmission Study Team.

Lancet. 2010 Mar 6;375(9717):824-33. doi: 10.1016/S0140-6736(09)62038-9. Epub 2010 Feb 12.

15.

Acyclovir and transmission of HIV-1 from persons infected with HIV-1 and HSV-2.

Celum C, Wald A, Lingappa JR, Magaret AS, Wang RS, Mugo N, Mujugira A, Baeten JM, Mullins JI, Hughes JP, Bukusi EA, Cohen CR, Katabira E, Ronald A, Kiarie J, Farquhar C, Stewart GJ, Makhema J, Essex M, Were E, Fife KH, de Bruyn G, Gray GE, McIntyre JA, Manongi R, Kapiga S, Coetzee D, Allen S, Inambao M, Kayitenkore K, Karita E, Kanweka W, Delany S, Rees H, Vwalika B, Stevens W, Campbell MS, Thomas KK, Coombs RW, Morrow R, Whittington WL, McElrath MJ, Barnes L, Ridzon R, Corey L; Partners in Prevention HSV/HIV Transmission Study Team.

N Engl J Med. 2010 Feb 4;362(5):427-39. doi: 10.1056/NEJMoa0904849. Epub 2010 Jan 20.

16.

Estimating the public health impact of the effect of herpes simplex virus suppressive therapy on plasma HIV-1 viral load.

Baggaley RF, Griffin JT, Chapman R, Hollingsworth TD, Nagot N, Delany S, Mayaud P, de Wolf F, Fraser C, Ghani AC, Weiss HA.

AIDS. 2009 May 15;23(8):1005-13. doi: 10.1097/QAD.0b013e32832aadf2.

17.

Comparison of CD4 cell count, viral load, and other markers for the prediction of mortality among HIV-1-infected Kenyan pregnant women.

Brown ER, Otieno P, Mbori-Ngacha DA, Farquhar C, Obimbo EM, Nduati R, Overbaugh J, John-Stewart GC.

J Infect Dis. 2009 May 1;199(9):1292-300. doi: 10.1086/597617.

18.

Impact of aciclovir on genital and plasma HIV-1 RNA in HSV-2/HIV-1 co-infected women: a randomized placebo-controlled trial in South Africa.

Delany S, Mlaba N, Clayton T, Akpomiemie G, Capovilla A, Legoff J, Belec L, Stevens W, Rees H, Mayaud P.

AIDS. 2009 Feb 20;23(4):461-9. doi: 10.1097/QAD.0b013e32831db217.

19.

Herpes simplex virus (HSV)-suppressive therapy decreases plasma and genital HIV-1 levels in HSV-2/HIV-1 coinfected women: a randomized, placebo-controlled, cross-over trial.

Baeten JM, Strick LB, Lucchetti A, Whittington WL, Sanchez J, Coombs RW, Magaret A, Wald A, Corey L, Celum C.

J Infect Dis. 2008 Dec 15;198(12):1804-8. doi: 10.1086/593214.

20.

Impact of small reductions in plasma HIV RNA levels on the risk of heterosexual transmission and disease progression.

Modjarrad K, Chamot E, Vermund SH.

AIDS. 2008 Oct 18;22(16):2179-85. doi: 10.1097/QAD.0b013e328312c756. Review.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk